Literature DB >> 12969573

Prediction of adverse outcome associated with vaginal misoprostol for labor induction.

M Mutlu Meydanli1, Eray Caliskan, Ali Haberal.   

Abstract

OBJECTIVE: To identify predictors of adverse outcome in pregnant women at term receiving 50 microg of intravaginal misoprostol for labor induction. STUDY
DESIGN: A prospective observational study was conducted of 720 pregnant women at term with an unfavorable cervix and a medical or obstetric indication for labor induction. All patients received 50 microg of intravaginal misoprostol every 4h up to three doses. The primary outcome measure was "adverse outcome" defined as: neonatal death, fetal acidemia and emergent cesarean delivery performed for non-reassuring fetal heart rate tracings. A stepwise logistic regression analysis was used to identify predictors of adverse outcome.
RESULTS: Tachysystole (frequent uterine contractions) (odds ratio (OR), 3.7; 95% confidence interval (CI), 1.2-10.8) and fetal tachycardia (OR, 4.8; 95% CI, 1.4-16.2) were determined as significant predictors of adverse outcome. The specificity of the model was 94.2%, whereas the sensitivity was 20.4%.
CONCLUSION: In the absence of tachysystole and fetal tachycardia, an uneventful delivery might be expected for women receiving 50 microg of intravaginal misoprostol.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12969573     DOI: 10.1016/s0301-2115(03)00105-2

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  2 in total

1.  Comparison of two dosing regimens of vaginal misoprostol for labour induction: a randomised controlled trial.

Authors:  Shivarudraiah Girija; Attibele Palaksha Manjunath
Journal:  J Turk Ger Gynecol Assoc       Date:  2009-12-01

2.  Intrapartum uterine activity and neonatal outcomes: a systematic review.

Authors:  Adam J Reynolds; Michael P Geary; Breda C Hayes
Journal:  BMC Pregnancy Childbirth       Date:  2020-09-12       Impact factor: 3.007

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.